Pancreatic polypeptide hypersecretion associated with a neuroendocrine carcinoma of the gallbladder.
The authors report a case of a suspected pure pancreatic polypeptide-secreting neuroendocrine carcinoma of the gallbladder. The tumor was initially interpreted as an adenocarcinoma of the gallbladder, but was found to have a neuroendocrine component after review. The pathology supports the view that a primitive epithelial stem cell can express both epithelial and neuroendocrine characteristics and can differentiate into both an adenocarcinoma and a neuroendocrine carcinoma. Upon recurrence, the tumor produced symptoms due to local growth, but eventually metastasized and led to the death of the patient within 4 years. The patient was treated with chemoembolization followed by the long-acting somatostatin analog octreotide acetate. The high serum level of pancreatic polypeptide may have contributed to cholestasis and cholelithiasis. Earlier measurement of serum hormone levels and identification of high pancreatic polypeptide levels may have suggested the presence of residual tumor and led to closer follow-up, imaging studies, and therapy.
Marrano
N N
NN
Hematology and Oncology of Northeast Georgia, Athens 30606, USA.
Blevins
L S
LS
Gal
A A
AA
McGuire
W P
WP
D000230:Adenocarcinoma / Q000175:diagnosis; D003937:Diagnosis, Differential; D017809:Fatal Outcome; D005260:Female; D005706:Gallbladder Neoplasms / Q000175:diagnosis* / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000175:diagnosis* / Q000378:metabolism* / Q000473:pathology; D010191:Pancreatic Polypeptide / Q000378:metabolism*
D010191:Pancreatic Polypeptide